Rhee Eugene P, Clish Clary B, Pierce Kerry A, Saad Ahmed, Lerman Lilach O, Textor Stephen C
aNephrology Division, Massachusetts General Hospital, Boston, Massachusetts bMetabolite Profiling, Broad Institute, Cambridge, Massachusetts cDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
J Hypertens. 2015 Apr;33(4):836-42. doi: 10.1097/HJH.0000000000000470.
To compare the metabolite profiles of venous effluent from both kidneys of individuals with unilateral atherosclerotic renal artery stenosis (ARAS) in order to directly examine how impaired renal blood flow impacts small-molecule handling in humans.
We applied liquid chromatography-mass spectrometry based metabolite profiling to venous plasma obtained from the stenotic (STK) and contralateral (CLK) kidneys of ARAS patients (n = 16), and both the kidneys of essential hypertensive controls (n = 11). Study samples were acquired during a 3-day protocol that included iothalamate clearance measurements, radiographic kidney phenotyping (Duplex ultrasound, multidetector computed tomography, and blood-oxygen-level-dependent MRI), and controlled sodium and caloric intake and antihypertensive treatment.
Partial least squares-discriminant analysis demonstrated clear separation of essential hypertensive kidney metabolite profiles versus STK and CLK metabolite profiles, but no separation between metabolite profiles of STK and CLK samples. All of the discriminating metabolites were similarly elevated in the STK and CLK samples, likely reflecting the lower glomerular filtration rate in the ARAS versus essential hypertensive individuals (mean 66.1 versus 89.2 ml/min per 1.73 m). In a paired analysis within the ARAS group, no metabolite was significantly altered in STK compared with CLK samples; notably, creatinine was the same in STK and CLK samples (STK/CLK ratio = 1.0, P = 0.9). Results were unchanged in an examination of ARAS patients in the bottom half of renal tissue perfusion or oxygenation.
Metabolite profiling does not differentiate venous effluent from STKs or CLKs in individuals with unilateral ARAS, despite the measurable loss of kidney volume and blood flow on the affected side. These findings are consistent with the kidney's ability to adapt to ARAS to maintain a range of metabolic functions.
比较单侧动脉粥样硬化性肾动脉狭窄(ARAS)患者双肾静脉流出液的代谢物谱,以直接研究肾血流受损如何影响人体小分子物质的处理。
我们对ARAS患者(n = 16)狭窄肾(STK)和对侧肾(CLK)以及原发性高血压对照者(n = 11)双肾的静脉血浆应用基于液相色谱 - 质谱的代谢物谱分析。研究样本在一个为期3天的方案中采集,该方案包括碘他拉酸盐清除率测量、肾脏影像学表型分析(双功超声、多排螺旋计算机断层扫描和血氧水平依赖性功能磁共振成像)以及控制钠和热量摄入及抗高血压治疗。
偏最小二乘判别分析表明原发性高血压肾代谢物谱与STK和CLK代谢物谱有明显区分,但STK和CLK样本的代谢物谱之间没有区分。所有有鉴别意义的代谢物在STK和CLK样本中均有类似升高,这可能反映了ARAS患者与原发性高血压个体相比肾小球滤过率较低(平均分别为66.1对89.2 ml/(min·1.73 m²))。在ARAS组内的配对分析中,与CLK样本相比,STK样本中没有代谢物有显著改变;值得注意的是,STK和CLK样本中的肌酐相同(STK/CLK比值 = 1.0,P = 0.9)。在对肾组织灌注或氧合处于下半部分的ARAS患者进行检查时,结果未改变。
尽管患侧肾脏体积和血流有可测量的减少,但代谢物谱分析无法区分单侧ARAS患者STK或CLK的静脉流出液。这些发现与肾脏适应ARAS以维持一系列代谢功能的能力一致。